Analysis finds intervention treatment arm takes longer, on average, to resolve adverse events
The above visualization is based on clinical trial data for an active treatment for eczema compared to placebo in adolescents that are unresponsive to standard care.
An analysis revealed that more adverse events were recorded for subjects that were assigned to an intervention treatment arm, compared to those assigned to a placebo.
See some of the insights below:
Of the 61 patients closely followed in the 12-month period, 49 developed adverse effects relating to anemia.
Subjects assigned to placebo treatment arm that reported an adverse event had their event treated in a duration of 6 days, on average. Participants assigned to interevention treatment, on average, saw the end of their adverse event in 8 days.